BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26329748)

  • 1. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.
    Wong AT; Safdieh JJ; Rineer J; Weiner J; Schwartz D; Schreiber D
    Int Urol Nephrol; 2015 Oct; 47(10):1629-34. PubMed ID: 26329748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
    Lediju O; Ikuemonisan J; Salami SS; Adejoro O
    J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
    Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
    Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
    Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
    Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.
    Gray PJ; Lin CC; Cooperberg MR; Jemal A; Efstathiou JA
    Eur Urol; 2017 May; 71(5):729-737. PubMed ID: 27597241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
    Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
    World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
    Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
    Lichtensztajn DY; Leppert JT; Brooks JD; Shah SA; Sieh W; Chung BI; Gomez SL; Cheng I
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1353-1360. PubMed ID: 30442735
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology.
    Gerhard RS; Patil D; Liu Y; Ogan K; Alemozaffar M; Jani AB; Kucuk ON; Master VA; Gillespie TW; Filson CP
    Urol Oncol; 2017 May; 35(5):250-256. PubMed ID: 28089387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
    Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
    World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.
    Tang C; Hoffman KE; Allen PK; Gabel M; Schreiber D; Choi S; Chapin BF; Nguyen QN; Davis JW; Corn P; Logothetis C; Ward J; Frank SJ; Navai N; McGuire SE; Anscher M; Pisters L; Pettaway CA; Kumar R; Linson P; Tripuraneni P; Tomaszewski JJ; Patel AB; Augspurger M; Kuban DA
    Cancer; 2020 Feb; 126(3):506-514. PubMed ID: 31742674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
    Chierigo F; Wenzel M; Würnschimmel C; Flammia RS; Horlemann B; Tian Z; Saad F; Chun FKH; Graefen M; Gallucci M; Shariat SF; Mantica G; Borghesi M; Suardi N; Terrone C; Karakiewicz PI
    J Urol; 2022 Feb; 207(2):375-384. PubMed ID: 34555930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
    Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
    Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.
    Mahal BA; Ziehr DR; Aizer AA; Hyatt AS; Sammon JD; Schmid M; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Lathan C; Kim SP; Trinh QD; Nguyen PL
    Urol Oncol; 2014 Nov; 32(8):1285-91. PubMed ID: 24846344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the treatment of localized prostate cancer using supplemented cancer registry data.
    Hamilton AS; Albertsen PC; Johnson TK; Hoffman R; Morrell D; Deapen D; Penson DF
    BJU Int; 2011 Feb; 107(4):576-84. PubMed ID: 20735387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
    Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
    Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
    Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.